These findings suggest that immunopathologic alterations that are caused by active EBV infections could be attributed to TLR3-mediated cytokinemia induced by EBER1, and that circulating EBER1 could be a potential target for therapeutic agents [84]. The gene discussed is TLR3; the disease is Epstein-Barr virus infection.